Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

angioedema - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

angioedema

MONDO:0010481

Also known as:Edemas, angioneuroticQuincke edemaQuincke oedema

Find Clinical TrialsTrials

Overview

Swelling involving the deep dermis, subcutaneous, or submucosal tissues, representing localized edema. Angioedema often occurs in the face, lips, tongue, and larynx.

Treatments7 FDA approved

Clinical Trials43 registered · 17 recruiting

Diagnosis

Biomarker and diagnostic research for angioedema has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

6 FDA-approved treatments are available for angioedema, including ICATIBANT ACETATE (FIRAZYR, approved 2011), C1 Esterase Inhibitor (Human) (Cinryze, approved 2008), and ECALLANTIDE (KALBITOR, approved 2009). An additional 1 compound holds orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

43 clinical trials registered, 17 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and gene therapy. Pipeline includes 3 PHASE4, 15 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07298447](https://clinicaltrials.gov/study/NCT07298447)

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 12:11 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of FIRAZYR for managing angioedema?
→Are any of the 43 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	75	45%
Patient case studies	28	17%
Disease patterns and progression	22	13%
Clinical study results	17	10%
Testing and diagnosis research	8	5%
Laboratory research	8	5%
Other research	7	4%
New treatment approaches	1	1%

Kisho

angioedema

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

From Sight to Stridor: Recurrent Angioedema in Systemic Lupus Erythematosus Associated With Complement Activation.

Dermatomyositis masquerading as angioedema: a crucial differential not to overlook.

angioedema

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

From Sight to Stridor: Recurrent Angioedema in Systemic Lupus Erythematosus Associated With Complement Activation.

Dermatomyositis masquerading as angioedema: a crucial differential not to overlook.